Nektar Gains 18% After Alopecia Trial Win and $250M Offering
Nektar Therapeutics reported positive clinical trial outcomes for its alopecia areata treatment, driving an 18.25% intraday rally to a 52-week high of $109. Wedbush lifted its price target to $95 from $70 and Nektar launched a $250 million public offering, adding capital but diluting shares.
1. Positive Clinical Trial Results
Nektar announced that its alopecia areata treatment achieved key endpoints in its latest clinical trial, marking a significant therapeutic advancement for hair loss patients. The data spurred an immediate market response, with shares jumping 18.25% to reach a 52-week high of $109.
2. Analyst Price Target Increase
Wedbush maintained its Neutral recommendation but raised its price target from $70 to $95, reflecting increased confidence in Nektar’s drug pipeline and commercial prospects. The $25 target boost signals improved valuation expectations despite the hold rating.
3. $250 Million Public Offering
To fund ongoing operations and future trials, Nektar initiated a $250 million public offering of common stock. While the capital infusion supports R&D activities, it also introduces potential share count dilution for existing investors.